Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

• Conditions: Non-muscle-invasive Bladder Cancer
• Interventions: Biological: Durvalumab (MEDI4736); Biological: Bacillus Calmette-Guerin (BCG)

• Registration Number: NCT03528694
• Lead Sponsor: AstraZeneca

Brief Summary

This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer

Detailed Description

Patients will be randomized in a 1:1:1 ratio to receive treatment with Durvalumab + BCG combination therapies, or Standard of Care (SoC) therapy.

Study Timeline

• Study First Submitted: 2018-02-28
• Study First Submitted QC: 2018-05-10
• Study Start: 2018-05-14
• Study First Posted: 2018-05-18
• Primary Completion: 2025-04-03
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-09
• Last Update Posted: 2025-05-11
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 1018

Inclusion Criteria

For inclusion in the study, patients should fulfill the following criteria:

• Aged at least 18 years

• BCG-naïve (patients who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before study entry are eligible)

• Local histological confirmation (based on pathology report) of high-risk transitional cell carcinoma of the urothelium of the urinary bladder confined to the mucosa or submucosa. A high risk tumor is defined as one of the following

  • T1 tumor
  • High grade/ G3 tumor
  • CIS
  • Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point)

• Complete resection of all Ta/T1 papillary disease prior to randomization, with the TURBT removing high-risk NMIBC performed not more than 4 months before randomization in the study. Patients with residual CIS after TURBT are eligible

• No prior radiotherapy for bladder cancer

• No prior exposure to immune-mediated therapy of cancer including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 antibodies. Patients who have been treated with anticancer vaccines will be excluded

Exclusion Criteria

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

• Evidence of muscle-invasive, locally advanced, metastatic, and/or extra vesical bladder cancer (ie, T2, T3, T4, and / or stage IV)

• Concurrent extravesical (ie, urethra, ureter, or renal pelvis), non-muscle-invasive transitional cell carcinoma of the urothelium

• Previous investigational product (IP) assignment in the present study

• Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for noncancer related conditions (eg, hormone replacement therapy) is acceptable. Chemotherapy for previous instances of NMIBC is acceptable.

• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

  • Patients with vitiligo or alopecia
  • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
  • Any chronic skin condition that does not require systemic therapy
  • Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician
  • Patients with celiac disease controlled by diet alone

• History of another primary malignancy except for

  • Malignancy treated with curative intent and with no known active disease ≥ 2 years before the first dose of IP and of low potential risk for recurrence during the study period
  • Adequately treated nonmelanoma skin cancer or lentigo maligna withoutevidence of disease
  • Adequately treated CIS without evidence of disease
  • Prostate cancer (tumor/node/metastasis stage) of stage ≤ T2cN0M0 without biochemical recurrence or progression that in the opinion of the Investigator does not require active intervention

• Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

  • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
  • Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Durvalumab plus BCG (induction + maintenance)	Bacillus Calmette-Guerin (BCG)	Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
Durvalumab plus BCG (induction + maintenance)	Durvalumab (MEDI4736)	Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
Durvalumab plus BCG (induction only)	Bacillus Calmette-Guerin (BCG)	Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
Durvalumab plus BCG (induction only)	Durvalumab (MEDI4736)	Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy
BCG treatment (Standard of care therapy)	Bacillus Calmette-Guerin (BCG)	Bacillus Calmette-Guerrin (BCG) standard of care treatment

Primary Outcome Measures

Name	Time	Method
The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC	Up to 4 years

Secondary Outcome Measures

Name	Time	Method
The serum concentration of Durvalumab plus BCG combination therapies	Up to 4 years
The immunogenicity of Durvalumab when used in combination with BCG treatment assessed by descriptive summary of presence of ADAs	Up to 4 years	Serum will be tested for the presence of anti-drug antibodies.
The efficacy of durvalumab + BCG combination therapy compared to SoC in terms of CRR for patients with CIS prior to study entry or at baseline cystoscopy	Up to 4 years	CRR at 6 months in patients with CIS prior to the study entry or at baseline cystoscopy
Disease-related symptoms and HRQoL in patients with NMIBC treated with Durvalumab + BCG combination therapies compared to SoC and compared to each other using the EORTC QLQ-C30 questionnaire	Up to 4 years	EORTC QLQ-C30 measures cancer patients' functioning (HRQoL) and symptoms for all cancer types and consists of functional, symptom and a global measure of health status scales
The efficacy of Durvalumab + BCG (induction plus maintenance) therapy compare to SoC in terms of OS	Up to 7 years
The efficacy of Durvalumab + BCG combination therapies compared to each other in terms of DFS after 24 months of last subject's last dose of IP	Up to 4 years
The efficacy of Durvalumab + BCG combination therapies compared to each other in terms of OS	Up to 7 years
The efficacy of Durvalumab + BCG combination therapies compared to each other in terms of time to muscle invasive bladder cancer and/or metastatic disease	Up to 7 years
Patient-reported treatment tolerability using specific PRO CTCAE symptoms	Up to 4 years
The efficacy of Durvalumab + BCG (induction only) combination therapy compared to SoC in terms of OS	Up to 7 years
The efficacy of Durvalumab + BCG (induction plus maintenance) therapy compare to SoC in terms of DFS after 24 months of last subject's last dose of IP	Up to 4 years
The efficacy of Durvalumab + BCG (induction only) combination therapy compared to SoC in terms of time to muscle invasive bladder cancer and/or metastatic disease	Up to 7 years
Disease-related symptoms and HRQoL in patients with NMIBC treated with Durvalumab + BCG combination therapies compared to SoC and compared to each other using the the EORTC QLQ NMIBC24 questionnaire	Up to 4 years	EORTC QLQ-NMIBC24 assesses disease-specific symptoms of patients with intermediate to high-risk NMIBC.
The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of time to muscle invasive bladder cancer and/or metastatic disease	Up to 7 years
The efficacy of Durvalumab + BCG (induction only) combination therapy compared to SoC in terms of DFS after 24 months of last subject's last dose of IP	Up to 4 years

Trial Locations

Locations (1)

Research Site; 🇬🇧 Taunton, United Kingdom